With one of the relatively newer but important anti-diabetic drugs, Vildagliptin manufactured by Novartis, losing patent protection in December, dozens of companies are readying plans to launch the generic version to get a slice of the action in the growing Rs 13,000-crore diabetes therapy. The cost of therapy is expected to reduce by over 50%.from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/30VklKU
Latest New Breaking News Today, National, World, Indian News Fast, English News Breaking, Latest English News, Breaking News, Read the Latest News On Business, Politics, Sports, Cream, Top Story, Cricket, Sports, Entertainment & Much More From India And Around The World, breaking news,city news,India news,international news,latest news,national news,world news,latest national news,breaking world news,trending news,current news,latest news India
No comments:
Post a Comment